Stem cell treatment study for people with late-stage HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 1/2 study tests whether mesenchymal stem cells can help people with HIV who have lower immune cell counts. You would join a treatment plan and follow study rules closely, while the researchers track safety and early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV infection and are age 18 to 65
- Your CD4+ T cell count is below 500 at the start of the study
- You have not had serious AIDS-related events recently and you can give consent
- You agree not to join any other studies or take other immune-fighting treatments during this study
- You do not have hepatitis B, C, D, or E infections based on blood tests
- You do not have HIV-2 infection (it must be HIV-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests targeted therapies to help HIV patients whose immune systems haven't fully recovered despite years of successful HIV medication. You may qualify if your CD4 count (a measure of immune health) stays low even though your viral load is undetectable.
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
This early-stage study tests whether CAR-T cells can help rebuild the immune system’s ability to fight HIV. You may be a candidate if your HIV is well controlled on standard treatment and you don’t have certain serious infections or organ problems.
This Phase 2 study tests whether donated-from-your-own-fat stem cells can improve outcomes for people who are high risk for getting COVID-19, but who have never had COVID-19 and test negative right now. It may help your immune system and reduce complications if you become infected during the study.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
This trial uses a special blood-filtering procedure (leukapheresis) along with blood tests to better understand how HIV affects the body. It may help researchers learn more about HIV “pathogenesis,” which means what drives disease in different people.
Hear when a new AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.